chemicals
Commented by André Will-Laudien on June 2nd, 2026 | 06:55 CEST
Stock Market Rotation Beyond AI: Opportunities in MustGrow, Bayer, and Novo Nordisk; Caution with K+S
Created and published on behalf of MustGrow Biologics Corp.
A shift in perspective remains the order of the day. Yesterday, the ECB met to discuss the current situation regarding inflation and interest rates. With an inflation rate of over 3% in Europe, there is likely no room for downward interest rate adjustments—quite the opposite! The 10-year yield on German government bonds has settled near the 3% mark over the past four weeks, while in the US, the 30-year yield is already above 5%. In the past, these were warning signs for a currently well-valued NASDAQ, as the so-called trailing P/E ratio has soared from 28 to 36. Growth companies, mostly financed through equity, thrive on tech euphoria, whereas capital-intensive industries, such as the life sciences sector, face a different situation. For example, Bayer and Novo Nordisk do not require market financing, as they hold large cash reserves. In the case of K+S, the ability to pass on prices to end customers could lead to rising cash flows, while the Canadian company MustGrow has only recently raised funds and is steadily continuing its rollout in the US. Mid-term investors should focus on sector rotation when tech momentum fades. The chances of a revival in neglected sectors look strong!
Read
Commented by Armin Schulz on May 28th, 2026 | 08:30 CEST
Bayer, MustGrow Biologics, K+S: The Secret Formula for Success Behind the Biological Fertilizer Revolution
Created and published on behalf of MustGrow Biologics Corp.
The global fertilizer industry is undergoing its most significant structural transformation in generations. A growing global population, technological breakthroughs in biological agricultural solutions, and policy shifts toward more sustainable agriculture are driving this growth sector. The need for more efficient nutrient use is giving rise to a dynamic market with fresh revenue potential. Companies that pursue the right strategies now are positioning themselves for the coming decade. Three players from different worlds embody this development in their own way: Bayer, MustGrow Biologics, and K+S.
Read
Commented by Fabian Lorenz on May 27th, 2026 | 07:50 CEST
SELL BASF and Hensoldt? BUY Recommendation for Power Metallic Mines
Caution is advised with Hensoldt. Analysts see a potential 30% downside for the stock. The company is trading at a premium to industry peers such as Rheinmetall and Renk, despite slower growth. While the partnerships with Helsing and Schwarz Digits are interesting, they are unlikely to contribute significantly to revenue in the foreseeable future. In contrast, analysts see 100% upside potential for Power Metallic Mines, specifically in the base-case scenario. The first resource estimate is scheduled for this summer. According to analyst estimates, the company could thus transition from a pure exploration valuation to a resource-based valuation phase sooner than previously expected. Analysts foresee difficult times ahead for BASF. The structural problems remain unresolved, and the stock is a "Sell". The chemical giant is attempting to counter these challenges through optimization measures and the increased use of AI technologies.
Read
Commented by Armin Schulz on May 26th, 2026 | 07:35 CEST
Forget Old Batteries — BYD, HPQ Silicon, and BASF are Capitalizing on the Upcoming Megatrend
Three players from completely different sectors share a common goal: the next-generation battery. BYD dominates electric mobility, BASF leads the global chemical industry, and HPQ Silicon is poised to take the next technological leap with innovative silicon anodes. While one secures sales and the other supplies critical cathode materials, the third embodies the bet on a revolution in energy density. This unique constellation of size, industrial clout, and risk offers investors a rare early-bird opportunity. BYD, HPQ Silicon, and BASF are now truly the ones to watch.
Read
Commented by Nico Popp on May 19th, 2026 | 07:30 CEST
Bottlenecks in the Hydrogen Network: What Linde and BASF Could Learn from A.H.T. Syngas
The "green" transformation of the European chemical industry is in danger of failing. Although the Federal Network Agency approved the German core hydrogen network—which is set to grow gradually to 9,040 km of hydrogen pipelines between 2025 and 2032—the actual rollout of this critical hydrogen route is not proceeding as planned. Without the rapid expansion of key hydrogen pipelines, the industry's transformation goals are virtually unattainable. While the infrastructure is slow in coming, regulatory pressure continues to intensify under the European RED III Directive. As delays mount in large-scale infrastructure projects, energy-intensive industrial companies are increasingly being forced to explore alternative solutions. Decentralized solutions are emerging as viable options. One company that could attract growing attention from both industry players and investors is A.H.T. Syngas.
Read
Commented by Fabian Lorenz on May 13th, 2026 | 07:30 CEST
Takeover at Bayer! Shock at Rheinmetall! Opportunity for MustGrow Stock!
Created and published on behalf of MustGrow Biologics Corp.
The blockade of the Strait of Hormuz is turning into a stress test for global food security. Supply chains across the fertilizer industry are coming under pressure — and this could create a significant opportunity for MustGrow Biologics. The company's organic biological fertilizer (biofertilizer) is being approved in an increasing number of US states. And in the field of biological crop protection, they are collaborating with Bayer. Meanwhile, Rheinmetall is grappling with disappointed market expectations. Revenues at the defence contractor are simply not growing fast enough, although the company continues to modernize its product portfolio.
Read
Commented by Armin Schulz on May 7th, 2026 | 08:45 CEST
From Niche Metal to Strategic Asset: Antimony Resources Gains Relevance for Rheinmetall and BASF
Created and published on behalf of Antimony Resources Corp.
What was long considered an obscure niche metal is now critical to the defence, chemical, and energy sectors. Antimony is used to harden alloys, improve flame resistance in plastics, and support certain battery technologies. At the same time, China controls 70% of production and strictly limits its exports. The result is price spikes of over 400% within two years. Without independent sources, Western industries risk being paralyzed. This is not a theoretical scenario, but an acute reality. Reason enough to take a closer look at the defence contractor Rheinmetall, the up-and-coming antimony producer Antimony Resources, and the chemical company BASF.
Read
Commented by André Will-Laudien on May 7th, 2026 | 08:25 CEST
Moving Ahead with Strong Concepts and Easing Tensions in the Middle East! MustGrow, K+S, Evotec, and Novo Nordisk in Focus
Created and published on behalf of MustGrow Biologics Corp.
What a headline: An agreement between the US and Iran – markets up 2% in just one minute! It can happen that fast. For investors, this is welcome news, as a de-escalation in the Iran conflict would significantly ease global supply chains and reduce pressure on critical transport routes. In particular, the Strait of Hormuz would lose some of its significance as a geopolitical risk factor, potentially stabilizing global flows of goods and energy. Easing tensions are also likely to lower transport costs again, shorten delivery times, and dampen price volatility. For companies in the food, healthcare, and agricultural technology sectors, this creates greater planning certainty and new growth opportunities. MustGrow Biologics and K+S could benefit from more stable agricultural markets, while Evotec and Novo Nordisk may gain additional tailwinds in a calmer healthcare environment. Investors are increasingly turning to stocks that promise sustainable growth and reliable returns in a more stable market setting. The key question now: will volatility finally decline as well?
Read
Commented by Armin Schulz on May 5th, 2026 | 07:10 CEST
How to Capitalize on Two of the Greatest Crises of Our Time – Thanks to Novo Nordisk, MustGrow Biologics, and Bayer
Created and published on behalf of MustGrow Biologics Corp.
While the world battles an obesity epidemic that has turned Novo Nordisk into a cash cow, a potential conflict with Iran threatens to tear apart global agricultural supply chains. More than 2.5 billion people are overweight, while war-induced fertilizer shortages could destroy crops. Two seemingly contradictory crises collide—pharmaceutical solutions for obesity on one side, biological crop protection products against famine on the other. It is precisely in this tension that three companies, each pursuing different approaches, are operating: Novo Nordisk, MustGrow Biologics, and Bayer.
Read
Commented by Nico Popp on May 1st, 2026 | 07:00 CEST
Long-established German companies under pressure: BASF, Lufthansa, and antimony pioneer Antimony Resources
Created and published on behalf of Antimony Resources Corp.
German industry is facing a severe test: recent media reports indicate that production shortages are already emerging due to the Strait of Hormuz blockade. Two crisis hotspots are converging. A military blockade of the world's most important energy trade route has restricted supplies of crude oil, liquefied natural gas (LNG), and chemical feedstocks such as methanol. At the same time, China is leveraging its dominance in critical minerals, such as antimony, to impose restrictive export controls, further drying up the market. In this environment, raw material sovereignty is the decisive competitive factor. While giants like BASF and Lufthansa are adapting their business models to the situation, problem solvers like Antimony Resources are moving into the spotlight.
Read